Following a period of relative exemption from escalating trade tensions, the global generic pharmaceutical industry is now facing the prospect…
Read More
Advancements in Alzheimer’s Disease Research Highlight Need for Subtype-Specific Treatments and Equitable Access to Diagnostics
The landscape of Alzheimer’s disease (AD) research and treatment is undergoing a significant transformation, marked by the recent advent of…
Read More
Japan Emerges as a Global Powerhouse for Regenerative Medicine Innovation
Japan is rapidly solidifying its position as a premier destination for regenerative medicine research and development, a surge driven by…
Read More
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Advertising of Obesity Drugs
The escalating rivalry between pharmaceutical giants Novo Nordisk and Eli Lilly has reached a new legal frontier, with Novo Nordisk…
Read More
AI Can Accelerate Study-Build Foundations, But Only When Teams Combine Targeted Automation with Standards, Traceability and Control.
Artificial intelligence (AI) is rapidly transforming various sectors, and clinical data management is no exception. While the potential applications of…
Read More
BMS claims pharma’s most powerful AI supercomputer. How it stacks up to Lilly’s and Roche’s.
Bristol Myers Squibb (BMS) announced Monday its plans to deploy an NVIDIA DGX SuperPOD, a cutting-edge, prepackaged supercomputing platform designed…
Read More
Samsung Biologics to Acquire PolyPeptide Group for SFr1.46 Billion, Expanding Peptide Therapeutics and CDMO Capabilities
Samsung Biologics has announced its intent to acquire PolyPeptide Group, a leading contract development and manufacturing organization (CDMO) specializing in…
Read More
New Therapies Usher in Era of Personalised Treatment for Rare Blood Cancers
A significant advancement in the treatment of rare blood cancers is set to transform the lives of approximately 200 patients…
Read More
The Inaugural EU Joint Clinical Assessment: Ojemda Sets Precedent Amidst Access Uncertainties
The European Union’s landmark Joint Clinical Assessment (JCA) for Ipsen’s orphan-designated drug Ojemda (tovorafenib) has been published, marking a significant…
Read More
Eli Lilly Acquires AtaiBeckley for $2.8 Billion, Marking Entry into Psychedelic Therapeutics
In a landmark move that signals a significant shift in pharmaceutical investment, Eli Lilly and Company has announced the acquisition…
Read More
